Cholangiocarcinoma · LIVING RESEARCH LIBRARY

Ongoing Research for Cholangiocarcinoma Using Advanced Alternative Medicine

Explore positive published findings by substance, cancer biology, treatment interaction and quality-of-life outcome.

Every entry includes the original study title, year, concise finding and a direct PubMed link.

Call 1.800.923.7878

Ask About Your Cholangiocarcinoma Case

Tell us the diagnosis, stage, biomarkers, current treatment plan and research questions you want to understand. Our Patient Care Team will follow up personally.

Prefer to speak now?
Call 1.800.923.7878

Explore this cancer section

Cholangiocarcinoma

Living research library · positive published findings

Research organized by substance and finding

Browse 15 source-linked studies with the full title, publication year, research focus and a concise finding. Select any linked substance to move directly to its corresponding Sunridge page.

Low Dose Berberine Suppresses Cholangiocarcinoma Cell Progression as a Multi-Kinase Inhibitor.

2022 · Cancer biology and response

Berberine (BBR), a natural isoquinoline alkaloid, possesses diverse pharmacological properties and anti-cancer effects that have been demonstrated in many in vitro and in vivo studies.

Open study on PubMed →

Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway.

2024 · Treatment response

Moreover, in vivo experiments showed that a combination curcumin and gemcitabine significantly reduced tumor size, tumor growth rate and LAT2 expression in a gemcitabine-resistant CCA xenograft mouse model.

Open study on PubMed →

Curcumin-Loaded Maltodextrin-Based Proniosomes Potentially Effective against Gemcitabine-Resistant Cholangiocarcinoma.

2025 · Treatment response

Curcumin has therapeutic potential with various anticancer properties.

Open study on PubMed →

Anticancer activities of epigallocatechin-3-gallate against cholangiocarcinoma cells.

2017 · Metastasis and invasion

Because it has chemopreventive and anti-invasive effect against various cancer cells, EGCG can be used to inhibit proliferation and invasion of cholangiocarcinoma (CCA) cells.

Open study on PubMed →

Ginsenoside (20)S-APPT induces ferroptosis in hepatocellular carcinoma and cholangiocarcinoma by targeting FSP1.

2025 · Apoptosis and cell death

In this study, we performed a phenotypic screen of a 180-compound natural product library and identified (20S)-protopanaxatriol ((20)S-APPT), a ginsenoside derivative, as a potent ferroptosis inducer with a favorable safety profile both in vitro and in vivo.

Open study on PubMed →

Possible role of ginseng as an additional therapy for cholangiocarcinoma therapy: A discussion on the role of vimentin suppression.

2023 · Cancer biology and response

The study reports possible role of ginseng as an additional therapy for cholangiocarcinoma therapy: A discussion on the role of vimentin suppression.

Open study on PubMed →

Beyond the Bile: Exploring the Microbiome and Metabolites in Cholangiocarcinoma.

2024 · Metabolism and redox biology

The role of the human microbiome in CCC is poorly understood, and a recent metagenomic analysis demonstrated a significant correlation between microbiome-associated carcinogenesis and CCC.

Open study on PubMed →

Causal roles of gut microbiota in cholangiocarcinoma etiology suggested by genetic study.

2024 · Cancer biology and response

Previous studies have implicated the gut microbiota in CCA, but evidence for causal mechanisms is lacking.

Open study on PubMed →

Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma.

2020 · Immune and inflammatory signaling

Therefore, in this study we aimed to improve our understanding of changes in gut microbiota, BA metabolism, and cytokines in patients with ICC.

Open study on PubMed →

Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.

2024 · Survival and clinical response

Higher tumor microbial α diversity was associated with lymph node metastasis and predicted shortened overall survival (OS) and recurrence-free survival (RFS).

Open study on PubMed →

Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma.

2023 · Cancer biology and response

We determined the characteristic profile of the intratumoral microbiota and the antitumor effect of P. fungorum in ICC.

Open study on PubMed →

Multicohort Validation of Gut Microbiome Signatures for Cholangiocarcinoma Diagnosis and Functional Characterization of Bifidobacterium Pseudocatenulatum.

2026 · Cancer biology and response

Growing evidence suggests a role for the gut microbiome in progression of cholangiocarcinoma (CCA), however, its diagnostic and therapeutic potential remains incompletely characterized.

Open study on PubMed →

ERRATUM: Quercetin Inhibits Intrahepatic Cholangiocarcinoma by Inducing Ferroptosis and Inhibiting Invasion via the NF-[Formula: see text]B Pathway.

2023 · Metastasis and invasion

The study reports eRRATUM: Quercetin Inhibits Intrahepatic Cholangiocarcinoma by Inducing Ferroptosis and Inhibiting Invasion via the NF-[Formula: see text]B Pathway.

Open study on PubMed →

Silibinin Therapy Improves Cholangiocarcinoma Outcomes by Regulating ERK/Mitochondrial Pathway.

2022 · Metabolism and redox biology

Inhibition of the ERK protein by silibinin led to a significant decrease in mitochondrial membrane potential, which, in turn, caused Cytochrome C to be released from the mitochondria.

Open study on PubMed →

Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients.

2021 · Cancer biology and response

Our results highlighted that vitamin D intake improves DFS in patients undergoing surgery.

Open study on PubMed →

Scottsdale Clinic

14200 N Northsight Blvd #160
Scottsdale, Arizona 85260

Office Hours

Monday–Friday: 9:00 AM–5:00 PM
Saturday: 9:00 AM–12:00 PM

Visit Sunridge in Scottsdale

FREE INTRODUCTORY CALL

Speak With Our Patient Care Team

Tell us what you are facing. There is no charge to speak with our Patient Care Team, understand how Sunridge works and determine whether a physician consultation may be an appropriate next step.

Call Now: 1-800-923-7878

This introductory call is not a medical consultation and does not establish a physician-patient relationship.

Have a Question or Share Feedback:
It's easy to get in touch with us